THYROGEN SIDE EFFECTS

  • Generic Name: thyrotropin alfa for injection
  • Brand Name: Thyrogen
Last updated on MDtodate: 10/12/2022

SIDE EFFECTS

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data described below reflect exposure to THYROGEN in 481 thyroid cancer patients who participated in a total of 6 clinical trials of THYROGEN: 4 trials for diagnostic use and 2 trials for ablation. In clinical trials, patients had undergone near-total thyroidectomy and had a mean age of 46.1 years. Thyroid cancer diagnosis was as follows: papillary (69.2%), follicular (12.9%), Hurthle cell (2.3%) and papillary/follicular (15.6%). Most patients received 2 intramuscular injections of 0.9 mg of THYROGEN injection gin 24 hours apart.

The safety profile of patients who have undergone thyroidectomy and received THYROGEN as adjunctive treatment for radioiodine ablation of thyroid tissue remnants for well-differentiated thyroid cancer did not differ from that of patients who received THYROGEN for diagnostic purposes.

Reactions reported in ≥1% of patients in the combined trials are summarized in Table 1. In some studies, an individual patient may have participated in both THYROGEN and thyroid hormone withdrawal [see Clinical Studies].

Table 1: Summary of Adverse Reactions by THYROGEN and Thyroid Hormone Withdrawal in Pooled Clinical Trials (≥1% of Patients in any Phase)

Preferred Term THYROGEN
(N=481)
n (%)
Thyroid Hormone Withdrawal
(N=418)
n (%)
Nausea 53 (11) 2 (<1)
Headache 29 (6) 0
Fatigue 11 (2) 2 (<1)
Vomiting 11 (2) 0
Dizziness 9 (2) 0 (0.0)
Asthenia 5 (1) 1 (<1)

 

Postmarketing Experience

The following adverse reactions have been identified during postapproval use of THYROGEN. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

  • Transient (<48 hours) influenza-like symptoms, including fever (>100°F/38°C), chills/shivering, myalgia/arthralgia, fatigue/asthenia/malaise, headache, and chills.
  • Hypersensitivity including urticaria, rash, pruritus, flushing, and respiratory signs and symptoms.
  • Injection site reactions, including pain, erythema, bruising, and pruritus.

 

SRC: NLM .